Browse by Medical Category
Not Accepting New Patients
Dr. Sam Moskowitz received his AB from Princeton Univ. in 1986 and MD magna cum laude in 1994 from Harvard Medical School. His research interests lie in the investigation of pediatric lung disease, particularly in cystic fibrosis and lung infection by Pseudomonas. He has held academic and clinical positions at Univ. of Washington School of Medicine and Seattle Children's Hospital, and is currently affiliated with MassGeneral Hospital for Children and Harvard Medical School.
View my most recent publications at PubMed
Praised by experts as a breakthrough for patients with a particular form of cystic fibrosis, ivacaftor was approved by the United States Food and Drug Administration (FDA) in January 2012 and is the first of its kind to treat the underlying defects of the disease, rather than manage its symptoms.
The Moskowitz research program at MGHfC focuses on chronic airway infection and host-pathogen interactions in cystic fibrosis (CF), encompassing the fields of microbiology, biochemistry, immunology, epithelial biology, bacterial and eukaryotic genetics, and pulmonary medicine.
Back to Top